Effect of Spironolactone on Acute Mountain Sickness,

Abstract

This study examined the effectiveness of Spironolactone as a prophylactic agent for the prevention of Acute Mountain Sickness (AMS). Spironolactone 25mg PO QID or placebo was administered to 9 subjects in a double-blind placebo controlled cross over design. Medication was given for 48h prior to and during a 46h exposure to 427 torr (4570m) in a hypobaric chamber. Six subjects demonstrated prevention of either the cerebral or respiratory symptoms of AMS during at least 1 segment of the altitude sojourn.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 11, 1985
Accession Number
ADA153780

Entities

People

  • Aaron J. Young
  • B. Edelman
  • C. S. Fulco
  • P. B. Rock
  • R. F. Larsen

Organizations

  • United States Army Research Institute of Environmental Medicine

Tags

DTIC Thesaurus Topics

  • Altitude
  • Barometric Pressure
  • Cerebral Edema
  • Chambers
  • Chemical Synthesis
  • Chemistry
  • Computer Programs
  • Computers
  • Data Analysis
  • Hypobaric Chambers
  • Hypobaric Conditions
  • Lactones
  • Military Research
  • Pain
  • Placebos
  • Sea Level
  • Side Effects

Fields of Study

  • Medicine

Readers

  • Marine Mammal Biology
  • Toxicology/Environmental Toxicology